REG - GlaxoSmithKline PLC - Issuance of Notes

GSKAnnouncement

23/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220323:nRSW6780Fa&default-theme=true

RNS Number : 6780F  GlaxoSmithKline PLC  23 March 2022

GlaxoSmithKline plc

Issued: 23 March 2022, London UK

 

 

 

ISSUANCE OF NOTES

 

GSK Consumer Healthcare Capital UK plc and GSK Consumer Healthcare Capital NL
B.V. (together with GSK Consumer Healthcare Capital UK plc, the "EMTN
Issuers") announce that, on 22 March 2022, they successfully priced the
following notes (the "EMTN Notes") under the GBP 10,000,000,000 Euro Medium
Term Note Programme of the EMTN Issuers:

-     GBP 300,000,000 2.875% Fixed Rate Senior Notes due 2028 and GBP
400,000,000 3.375% Fixed Rate Senior Notes due 2038, each issued  by GSK
Consumer Healthcare Capital UK plc; and

 

-     EUR 850,000,000 1.250% Fixed Rate Notes due 2026, EUR 750,000,000
1.750% Fixed Rate Senior Notes due 2030 and EUR 750,000,000 2.125% Fixed Rate
Senior Notes due 2034, each issued by GSK Consumer Healthcare Capital NL B.V.

 

In addition, GSK Consumer Healthcare Capital UK plc and GSK Consumer
Healthcare Capital US LLC announce that, on 21 March 2022, they successfully
priced the following notes (the "144A Notes") pursuant to an Offering
Memorandum dated 21 March 2022:

 

-     USD 700,000,000 3.024% Callable Fixed Rate Senior Notes due 2024,
USD 300,000,000 Callable Floating Rate Senior Notes due 2024, USD
2,000,000,000 3.375% Fixed Rate Senior Notes due 2027, USD 1,000,000,000
3.375% Fixed Rate Senior Notes due 2029, USD 2,000,000,000 3.625% Fixed Rate
Senior Notes due 2032 and USD 1,000,000,000 4.000% Fixed Rate Senior Notes due
2052, each issued by GSK Consumer Healthcare Capital US LLC; and

 

-     USD 1,750,000,000 3.125% Fixed Rate Senior Notes due 2025 issued by
GSK Consumer Healthcare Capital UK plc.

The EMTN Notes and the 144A Notes (together, the "Notes") will be guaranteed
by GlaxoSmithKline plc up to and excluding the Guarantee Assumption Date (as
defined in the Terms and Conditions of the Notes).

 

For further information, please contact:

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

 UK Media enquiries:                   David Mawdsley Simon Steel  +44 (0) 20 8047 5502   (London)

                                       Tim Foley                   +44 (0) 20 8047 5502   (London)

                                                                   +44 (0) 20 8047 5502   (London)

 European Analyst/Investor enquiries:  James Dodwell               +44 (0) 20 8047 2406   (London)

                                       Danielle Smith              +44 (0) 20 8047 0932   (London)

 

 

IMPORTANT DISCLAIMER: This announcement does not constitute an offer of any
securities for sale (including, without limitation, any Notes). The offer and
sale of the Notes may be restricted by law in certain jurisdictions.

This document does not constitute, or form part of, an offer to sell, or a
solicitation of an offer to purchase, any securities in the United States of
America (including its territories and possessions, any state of the United
States of America and the District of Columbia) (the "United States"). The
securities referred to herein have not been and will not be registered under
the U.S. Securities Act of 1933, as amended (the "Securities Act") or under
the securities laws of any state of the United States, and may not be offered,
sold, resold or delivered directly or indirectly, in or into the United States
or to a U.S. person absent registration or an applicable exemption from, or in
a transaction not subject to, the registration requirements of the Securities
Act.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODDDGDXXSDDGDD